Somatostatin, Octreotide, Pentoxyfilline in the Prevention of Post-ERCP Pancreatitis and Molecular Markers

This study has been completed.
Sponsor:
Information provided by:
University of Ioannina
ClinicalTrials.gov Identifier:
NCT00222092
First received: September 13, 2005
Last updated: August 23, 2011
Last verified: September 2005

September 13, 2005
August 23, 2011
September 2005
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00222092 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Somatostatin, Octreotide, Pentoxyfilline in the Prevention of Post-ERCP Pancreatitis and Molecular Markers
Effect of Octreotide, Somatostatin, Pentoxyfilline or Placebo in the Prevention and the Course of Post-ERCP Pancreatitis and Study of Molecular Markers in Post-ERCP Pancreatitis

Octreotide, somatostatin and pentoxyfilline commercially available drugs that are used in various clinical situations. They are safe and known for years. Octreotide and somatostatin have been used in many studies for the prophylaxis and treatment of pancreatitis and post-ERCP pancreatitis, while pentoxyfilline has shown effect on patients with alcoholic hepatitis, obstructive vasculitis etc. The aim of the study is to evaluate the efficacy of any of those treatments for the prophylaxis and treatment of post-ERCP pancreatitis. In addition some molecular markers of acute and chronic inflammation will be measured before and after the endoscopic procedures according to the study protocol.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

patients undergoing endoscopic retrograde cholangiopancreatography

Post-ERCP Acute Pancreatitis
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
300
September 2006
Not Provided

Inclusion Criteria:

  • patients undergoing endoscopic retrograde cholangiopancreatography

Exclusion Criteria:

  • children, pregnant or breastfeeding women
  • patients with coagulation disorders
  • inability to access the papilla of Vater due to technical difficulties (previous surgery, malignant obstruction)
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Greece
 
NCT00222092
SIG-2005
Not Provided
Not Provided
University of Ioannina
Not Provided
Principal Investigator: Dimitrios Sigounas, MD University of Ioannina
University of Ioannina
September 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP